Skip to content
Company
About
Leadership
Board Members
Scientific Advisory Board
Pipeline
Overview
Immuno-Oncology and shedding blockers
BND-22
BND-35
BND-67
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
Company
About
Leadership
Board Members
Scientific Advisory Board
Pipeline
Overview
Immuno-Oncology and shedding blockers
BND-22
BND-35
BND-67
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
News
Publications
Events & Press
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Journal for ImmunoTherapy of Cancer / Sep 22, 2022
Poster Presentation With Sanofi presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
ASCO 2022 Annual Meeting
BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models
Poster Presentations at AACR 2020 Virtual Annual Meeting
